Company profile: Sherlock Biosciences
1.1 - Company Overview
Company description
- Provider of engineering biology-based molecular diagnostics leveraging CRISPR and synthetic biology, including SHERLOCK for DNA/RNA detection and INSPECTR for instrument-free ambient tests, plus an FDA-authorized CRISPR SARS-CoV-2 kit. Offers global health partnerships to develop and distribute affordable infectious disease diagnostics and an internship & co-op program.
Products and services
- SHERLOCK: A CRISPR-based diagnostic system that detects specific DNA or RNA sequences from pathogens or organisms, adaptable for use across various settings
- CRISPR-based SARS-CoV-2 kit: The first FDA-authorized diagnostic product for qualitative detection of SARS-CoV-2 nucleic acid, delivering accurate results rapidly across a vast range of needs in virtually any setting
- INSPECTR: A synthetic biology-based platform that creates instrument-free, simple-to-use diagnostic tests operating at ambient temperature for straightforward deployment across diverse testing environments
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sherlock Biosciences
OnCore Biopharma
HQ: United States
Website
- Description: Provider of biotechnology research, development, and commercialization of therapies for chronic hepatitis B virus (HBV) infection, assembling a portfolio of novel product candidates with unique mechanisms of action for the treatment of hepatitis B.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OnCore Biopharma company profile →
Infant Bacterial Therapeutics
HQ: Sweden
Website
- Description: Provider of clinical-stage pharmaceutical drug development focused on influencing the infant microbiome to prevent or treat rare diseases in infants. Developing IBP-9414 to prevent NEC in premature infants; IBP-9414 contains the active substance Lactobacillus reuteri, a human bacterial strain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Infant Bacterial Therapeutics company profile →
Pattern Bioscience
HQ: United States
Website
- Description: Provider of biotech diagnostic solutions to combat antibiotic resistance, including Digital Culture Technology, a single-cell analysis platform using digital cell reactors and machine learning to rapidly diagnose complex bacterial infections and determine antibiotic response without traditional culture, and the Pneumonia Action Panel for fast, comprehensive pathogen identification and susceptibility in hospitalized severe pneumonia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pattern Bioscience company profile →
Cubist
HQ: United States
Website
- Description: Provider of biopharmaceutical products focused on the research, development, and commercialization of therapies addressing unmet medical needs in the acute care environment; markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cubist company profile →
Trillium Diagnostics
HQ: United States
Website
- Description: Provider of cellular diagnostics offering insight into human disease as a healthcare center.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trillium Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sherlock Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sherlock Biosciences
2.2 - Growth funds investing in similar companies to Sherlock Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sherlock Biosciences
4.2 - Public trading comparable groups for Sherlock Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →